Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Miura R, Ono A, Nakahara H, Shirane Y, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Murakami E, Kawaoka T, Miki D, Tsuge M, Kishi T, Ohishi W, Sakamoto N, Arihiro K, Hayes CN, Oka S. Miura R, et al. Among authors: ohishi w. J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02185-w. Online ahead of print. J Gastroenterol. 2024. PMID: 39652104
Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.
Fujino H, Imamura M, Nagaoki Y, Kawakami Y, Abe H, Hayes CN, Kan H, Fukuhara T, Kobayashi T, Masaki K, Ono A, Nakahara T, Honda Y, Naeshiro N, Urabe A, Yokoyama S, Miyaki D, Murakami E, Kawaoka T, Hiraga N, Tsuge M, Hiramatsu A, Hyogo H, Aikata H, Takahashi S, Miki D, Ochi H, Ohishi W, Chayama K; Hiroshima Liver Study Group. Fujino H, et al. Among authors: ohishi w. J Gastroenterol. 2014 Dec;49(12):1548-56. doi: 10.1007/s00535-013-0924-9. Epub 2013 Dec 21. J Gastroenterol. 2014. PMID: 24362944 Clinical Trial.
The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients.
Kurihara M, Tsuge M, Murakami E, Mori N, Ohishi W, Uchida T, Fujino H, Nakahara T, Abe-Chayama H, Kawaoka T, Miki D, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Zhang Y, Makokha GN, Hayes CN, Chayama K. Kurihara M, et al. Among authors: ohishi w. Antivir Ther. 2018;23(3):239-248. doi: 10.3851/IMP3196. Antivir Ther. 2018. PMID: 28933704
Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib.
Ono A, Aikata H, Yamauchi M, Kodama K, Ohishi W, Kishi T, Ohya K, Teraoka Y, Osawa M, Fujino H, Nakahara T, Murakami E, Miki D, Kawaoka T, Abe-Chayama H, Zhang P, Liu S, Makokha GN, Tsuge M, Imamura M, Hayes CN, Chayama K. Ono A, et al. Among authors: ohishi w. Ther Adv Med Oncol. 2020 May 20;12:1758835920922051. doi: 10.1177/1758835920922051. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32547646 Free PMC article.
Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma.
Yamauchi M, Ono A, Amioka K, Fujii Y, Nakahara H, Teraoka Y, Uchikawa S, Fujino H, Nakahara T, Murakami E, Okamoto W, Miki D, Kawaoka T, Tsuge M, Imamura M, Hayes CN, Ohishi W, Kishi T, Kimura M, Suzuki N, Arihiro K, Aikata H, Chayama K, Oka S. Yamauchi M, et al. Among authors: ohishi w. Commun Med (Lond). 2023 Oct 25;3(1):152. doi: 10.1038/s43856-023-00390-x. Commun Med (Lond). 2023. PMID: 37880538 Free PMC article.
Differences in serum microRNA profiles in hepatitis B and C virus infection.
Akamatsu S, Hayes CN, Tsuge M, Miki D, Akiyama R, Abe H, Ochi H, Hiraga N, Imamura M, Takahashi S, Aikata H, Kawaoka T, Kawakami Y, Ohishi W, Chayama K. Akamatsu S, et al. Among authors: ohishi w. J Infect. 2015 Mar;70(3):273-87. doi: 10.1016/j.jinf.2014.10.017. Epub 2014 Nov 5. J Infect. 2015. PMID: 25452043
Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy.
Kitamura S, Tsuge M, Hatakeyama T, Abe H, Imamura M, Mori N, Saneto H, Kawaoka T, Mitsui F, Hiraga N, Takaki S, Kawakami Y, Aikata H, Takahashi S, Ohishi W, Ochi H, Hayes CN, Chayama K. Kitamura S, et al. Among authors: ohishi w. Antivir Ther. 2010;15(8):1087-97. doi: 10.3851/IMP1674. Antivir Ther. 2010. PMID: 21149915
89 results